Bryan J Schneider

Summary

Affiliation: Cornell University
Country: USA

Publications

  1. pmc Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, 1305 York Avenue, 7th Floor, New York, NY 10021, USA
    Invest New Drugs 31:435-42. 2013
  2. doi Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, 525 East 68th Street, J 321, New York, NY 10021, USA
    Invest New Drugs 27:571-8. 2009
  3. doi Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, 525 East 68th Street, 3rd Floor, New York, NY 10065, USA
    Invest New Drugs 30:249-57. 2012
  4. doi Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer
    Bryan J Schneider
    Department of Internal Medicine, Weill Cornell Medical College, New York, NY, USA
    Clin Lung Cancer 11:223-7. 2010
  5. doi Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York City, New York, USA
    J Thorac Oncol 6:1117-20. 2011
  6. ncbi Surgery for early-stage small cell lung cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York 10021, USA
    J Natl Compr Canc Netw 9:1132-9. 2011
  7. pmc Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy
    Bryan J Schneider
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, Michigan, USA
    J Thorac Oncol 3:1454-9. 2008
  8. ncbi Systemic therapy for small cell lung cancer
    Benjamin Levy
    Division of Hematology Oncology, Department of Internal Medicine, Beth Israel Comprehensive Cancer Center, New York, New York, USA
    J Natl Compr Canc Netw 11:780-7. 2013
  9. ncbi Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0848, USA
    Cancer 110:770-5. 2007
  10. ncbi Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 63:1325-30. 2005

Detail Information

Publications13

  1. pmc Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, 1305 York Avenue, 7th Floor, New York, NY 10021, USA
    Invest New Drugs 31:435-42. 2013
    ..However, the challenges associated with prolonged administration limit further investigation...
  2. doi Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, 525 East 68th Street, J 321, New York, NY 10021, USA
    Invest New Drugs 27:571-8. 2009
    ....
  3. doi Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, 525 East 68th Street, 3rd Floor, New York, NY 10065, USA
    Invest New Drugs 30:249-57. 2012
    ..We conducted a phase I trial to determine the dose level of vorinostat plus docetaxel that would result in dose-limiting toxicity (DLT) in ≤30% of patients...
  4. doi Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer
    Bryan J Schneider
    Department of Internal Medicine, Weill Cornell Medical College, New York, NY, USA
    Clin Lung Cancer 11:223-7. 2010
    ..This trial was designed to evaluate irinotecan/cisplatin plus maintenance imatinib in patients with c-Kit-positive disease (the transmembrane receptor c-Kit is the product of the c-KIT protooncogene)...
  5. doi Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York City, New York, USA
    J Thorac Oncol 6:1117-20. 2011
    ..The prognosis for patients with extensive-stage small cell lung cancer remains poor. This trial was designed to evaluate the efficacy and toxicity of maintenance sunitinib after platinum-etoposide chemotherapy...
  6. ncbi Surgery for early-stage small cell lung cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, New York 10021, USA
    J Natl Compr Canc Netw 9:1132-9. 2011
    ..This article reviews the available literature, and proposes guidelines for including potentially curative resection in the management of patients with limited-stage small cell lung cancer...
  7. pmc Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy
    Bryan J Schneider
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, Michigan, USA
    J Thorac Oncol 3:1454-9. 2008
    ..To evaluate the efficacy and toxicity of the combination of celecoxib and docetaxel in patients with advanced non-small cell lung cancer after failure of platinum-based therapy...
  8. ncbi Systemic therapy for small cell lung cancer
    Benjamin Levy
    Division of Hematology Oncology, Department of Internal Medicine, Beth Israel Comprehensive Cancer Center, New York, New York, USA
    J Natl Compr Canc Netw 11:780-7. 2013
    ..Recently, scientific efforts have identified potentially actionable genetic alterations in small cell tumors that may lead to the development of effective, targeted therapies. ..
  9. ncbi Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0848, USA
    Cancer 110:770-5. 2007
    ..The purposes of this study were to evaluate efficacy and toxicity of the combination of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site (CUP)...
  10. ncbi Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, USA
    Int J Radiat Oncol Biol Phys 63:1325-30. 2005
    ..To control micrometastatic disease, combination chemotherapy (gemcitabine and cisplatin) before and after combined modality therapy (CMT) was planned...
  11. ncbi Preoperative chemoradiation for the treatment of locoregional esophageal cancer: the standard of care?
    Bryan J Schneider
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Medical Center, Ann Arbor, MI, USA
    Semin Radiat Oncol 17:45-52. 2007
    ..There is no absolute standard that is best for all patients; rather, the physician and patient working in concert eventually determine which of several reasonable treatment options is best suited for that individual patient...
  12. doi Personalized Therapy of Small Cell Lung Cancer
    Bryan J Schneider
    Division of Hematology Oncology, University of Michigan, C411 Med Inn SPC 5848, 1500 E Medical Center Dr, Ann Arbor, MI, 48109 5848, USA
    Adv Exp Med Biol 890:149-74. 2016
    ....
  13. doi Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent
    Ashish Saxena
    Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, 1305 York Avenue, 7th Floor, New York, NY, 10021, USA
    Med Oncol 33:13. 2016
    ..Single-agent nab-paclitaxel was well tolerated and demonstrated efficacy in advanced NSCLC patients with relapsed or platinum-refractory disease. Further prospective clinical trials with nab-paclitaxel in these settings are warranted. ..